Chronic Obstructive Pulmonary Disease | DecisionBase | US/EU5 | 2014
Amid the Emergence of a Novel Class of Dual Bronchodilators, What Are the Key Areas of Opportunity for Differentiation According to Pulmonologists and Payers?
Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and polypharmacy is commonplace as patients’ COPD worsens. Substantial opportunity exists for a disease-modifying therapy, but development of new COPD therapies has focused instead on therapies that combine two bronchodilators into one inhaler. As the COPD marketplace becomes increasingly crowded, emerging therapies will need to be clearly differentiated from competitors to garner substantial uptake.
Related Market Assessment Reports
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
